Embrace
the new year
and make a difference!
This new year, why not take on a challenge that not only pushes you but also makes a positive impact for people affected by Parkinson’s?
We fund research that
slows, stops or reverses Parkinson’s
Understanding Parkinson's
In Parkinson’s a protein called alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and it is believed that this process could be toxic. Cure Parkinson's is investigating how this and other key biochemical pathways and events contribute to the progression of Parkinson's. Thanks to our supporters, we’re funding research into the most promising therapeutic areas.
Find out moreParkinson's and diabetes
In 2017 results of a large phase 2 clinical trial showed that exenatide, a drug used to treat diabetes, may slow the progression of Parkinson’s. This trial added further evidence to exenatide’s potential as a drug that might interrupt the progression of Parkinson’s; it paved the way for the large phase 3 clinical trial that is now underway. Cure Parkinson’s is co-funding two sub-studies in this promising phase of research into exenatide for Parkinson’s.
Find out more here
Take part in research
PD Frontline #GetTrialReady
PD Frontline is a remote study offering online genetic testing for people with Parkinson’s, so they can be referred to appropriate clinical trials and other studies. The registration process is designed to be quick and easy to navigate, and it only takes 10 minutes to complete!
Donate
Please consider donating today to help us progress our research with urgency towards a cure
Fundraising events
Advocate spotlight
Alison Anderson, Cheltenham
Alison Anderson was diagnosed with early onset Parkinson’s in 2015, aged 46. Originally from Dundee, Scotland, Alison lives in Cheltenham with her husband and three sons. Undeterred by her condition, Alison has taken on some major cycling challenges to raise funds and awareness for Cure Parkinson's.
Read more of her story
